Author: Customer Service

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., Aug. 14, 2026 (GLOBE NEWSWIRE) — LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2026, and provided recent pipeline and business updates. “We enter the second half of 2026 with a clear focus on executing our Phase 3 ELAINE-3 trial and advancing lasofoxifene toward what we believe could be a transformative treatment option for patients with ESR1-mutated metastatic breast cancer,” said Mark Litton, Ph.D., President and Chief Executive...

— $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval — ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. Corporate Highlights from 2Q 2026 to dateCompleted $30 million private placement with potential proceeds of up to $90 million upon full cash exercise of warrants. Regained compliance with Nasdaq Listing Requirements. Issuance of patents in the U.S....

Key Facts At-a-GlanceWho: Ambow Education Holding Ltd. (NYSE American: AMBO) What: Unaudited financial and operating results for the three-month and six-month periods ended June 30, 2026 When: Reported August 14, 2026; Quarterly Report on Form 10-Q filed with the SEC the same day First Half Revenue: Net revenues increased 2.0% to $5.2 million from $5.1 million in the first half of 2025 Second Quarter Revenue: Net revenues decreased 14.3% to $2.4 million from $2.8 million in the second quarter of 2025 Margin: First half gross profit margin expanded to 55.8% from 54.9% Balance Sheet: Cash resources of $7.2 million as of June 30, 2026, and positive working capital of $5.5 millionCUPERTINO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO), an innovator in AI-powered...

SHOEMAKERSVILLE, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced financial results for its second quarter ended June 30, 2026. Comparison of Second Quarter vs. Prior Year Period:Net sales decreased to $23.2 million compared to $39.2 million. Gross Profit Margin increased to 11.3% of net sales compared to 7.1%. Adjusted Gross Profit Margin(1) increased to 20.0% of net sales compared to 19.2%. SG&A expense and Adjusted SG&A(1) expense decreased by 37.7% and 35.7%, respectively. Net loss decreased to $10.6 million compared to $16.9 million. Adjusted EBITDA(1) of $(1.7) million compared to $(2.3) million. Cash...

GROVER, N.C., Aug. 14, 2026 (GLOBE NEWSWIRE) — Ebang International Holdings Inc. (Nasdaq: EBON) (the “Company,” “we,” “us” or “our”), today announced its unaudited financial results for the first half of fiscal year 2026. Operational and Financial Highlights for the Six Months Ended June 30, 2026 Total net revenues reached approximately US$3.92 million for the first half of 2026, representing a 9.54% increase compared to approximately US$3.58 million in the same period of 2025. Gross profit improved to approximately US$0.73 million for the first half of 2026, compared to a gross loss of approximately US$0.65 million in the prior-year period. Net loss was approximately US$5.54 million for the first half of 2026, compared to approximately US$4.50 million in the prior-year period. “In the first half of fiscal year 2026, amid the accelerating...

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026:Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025. Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 2025. Operating expenses were approximately $2.33 million for the second quarter of 2026, compared with approximately $1.86 million for the second...

MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026. On June 16, 2026, the Company announced its preliminary human data readout for the first two cohorts in a dose-escalating Phase 1 clinical study to evaluate HCW9302 as a monotherapy in patients with alopecia areata. HCW9302 is a fusion immunotherapeutic which is potentially a best-in-class IL-2-based treatment for autoimmune diseases. These preliminary findings support the Company’s belief that HCW9302 has the potential to activate...